(Q35157385)

6 August 2017

title

Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma (English)

1 reference

6 August 2017

21

Sergio Giralt

1 reference

6 August 2017

7

Elizabeth Shpall

1 reference

6 August 2017

4

Chitra Hosing

1 reference

6 August 2017

1

Uday Popat

1 reference

6 August 2017

2

Rima Saliba

1 reference

6 August 2017

20

Richard Champlin

1 reference

6 August 2017

14

Issa Khouri

1 reference

6 August 2017

10

Amin Alousi

1 reference

6 August 2017

12

Yago Nieto

1 reference

6 August 2017

5

Muzaffar Qazilbash

1 reference

6 August 2017

13

Partow Kebriaei

1 reference

6 August 2017

3

Rupinderjit Thandi

1 reference

6 August 2017

8

John McMannis

1 reference

6 August 2017

9

Martin Körbling

1 reference

6 August 2017

17

Sheeba Thomas

1 reference

6 August 2017

19

Roy Jones

1 reference

6 August 2017

Paolo Anderlini

6

1 reference

6 August 2017

Borje Andersson

11

1 reference

6 August 2017

Marcos de Lima

15

1 reference

6 August 2017

Donna Weber

16

1 reference

6 August 2017

Michael Wang

18

1 reference

6 August 2017

publication date

8 April 2009

1 reference

Biology of Blood and Marrow Transplantation

6 August 2017

published in

1 reference

6 August 2017

volume

15

1 reference

6 August 2017

issue

6

1 reference

6 August 2017

page(s)

718-723

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4352933

6 August 2017

1 reference

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4352933

Management of multiple myeloma: the changing landscape

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4352933

Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4352933

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4352933

Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4352933

PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4352933

Treatment of plasma cell dyscrasias with thalidomide and its derivatives

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4352933

28 July 2018

Stem cell mobilization.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4352933

A phase 2 study of bortezomib in relapsed, refractory myeloma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4352933

Antitumor activity of thalidomide in refractory multiple myeloma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4352933

Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4352933

Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4352933

Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4352933

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4352933

Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4352933

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4352933

Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4352933

A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4352933

DTPACE: an effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4352933

Thalidomide and dexamethasone for resistant multiple myeloma

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4352933

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4352933

Thalidomide alone or with dexamethasone for previously untreated multiple myeloma

27 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4352933

Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma

27 September 2018

1 reference

12 December 2020

Mobilization of CD34+ cells in elderly patients (>/= 70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen

1 reference

12 December 2020

Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial

1 reference

12 December 2020

Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma

1 reference

12 December 2020

Factors that influence collection and engraftment of autologous peripheral-blood stem cells

1 reference

12 December 2020

A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome

1 reference

12 December 2020

10.1016/J.BBMT.2009.02.011

Identifiers

DOI

1 reference

6 August 2017

1 reference

6 August 2017

1 reference